OncRef

Clinical Trial: NCT05838066

Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.

Status:

RECRUITING

Phase:

Phase 3

Lead Sponsor:Shanghai JMT-Bio Inc.
Information Provided By:Shanghai JMT-Bio Inc.
Last Update Posted:2025-05-30

Study Overview

Brief Summary

This is a randomized, controlled, open-label, multicenter, phase Ш clinical study designed to compare the efficacy and safety of KN026 in combination with HB1801 to trastuzumab in combination with pertuzumab and docetaxel in the first-line treatment of subjects with HER2-positive recurrent or metastatic breast cancer. The statistical assumption for this study is superiority. The primary study endpoint was PFS as assessed by Blinded Independ Review Committee (BIRC).

Official Title

A Randomized, Controlled, Open-label, Multicenter, Phase Ш Clinical Study of the Efficacy and Safety of KN026 in Combination With HB1801 Versus Trastuzumab in Combination With Pertuzumab and Docetaxel in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.

Conditions

First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer

Intervention / Treatment

  • Drug: Recombinant Humanized Bispecific antibody against HER2,KN026
  • Drug: HB1801
  • Drug: Pertuzumab
  • Drug: Trastuzumab
  • Drug: Docetaxel

Other Study ID Numbers

  • KN026-003

Start Date (Actual)

2023-07-23

Primary Completion Date (Estimated)

2025-07-31

Study Completion Date (Estimated)

2027-12-31

Enrollment (Estimated)

880

Study Type

Interventional

Phase

Phase 3